Sanofi Shares Drop 1.22% at Close on Tuesday, January 20
The stock of the French pharmaceutical company closed at 78.03 euros this Tuesday, January 20, 2026, amid marked volatility. Following several downward revisions of targets and a challenging stock market journey since the start of the year, Sanofi continues its correction despite some recent regulatory progress in China and Europe.
Stock Performance Details
The stock fell by 1.22% this Tuesday compared to the previous day's close at 78.99 euros. Over the week, the decline now stands at 5.32%, and it has reached nearly 20.53% over the past year, indicating a prolonged lack of investor confidence. Technically, the RSI at 39 suggests a situation close to the oversold zone without fully entering it, while the price is significantly below the 50-day and 200-day moving averages, at 84.22 and 85.51 euros respectively. This setup confirms a deteriorated technical environment, further accentuated by a recent breach of the support threshold at 78.99 euros.
Strategic Acquisitions and Regulatory Approvals
The group is preparing an improved offer to acquire American biotech firm Ocular Therapeutix, following the rejection by its board of a previous proposal at 16 dollars per share, reported on January 15. This acquisition effort is part of the laboratory's diversification strategy in anticipation of the patent loss for Dupixent in the early 2030s. Additionally, two new drugs licensed by Sanofi, Myqorzo and Redemplo, received approval in China on January 15, while Tzield was granted European approval on January 12. Regarding analyst recommendations, Deutsche Bank maintains a buy rating with a target reduced to 105 euros on January 16, representing a potential increase of over 34% from the current price. Conversely, UBS has downgraded the stock to neutral, with a target now set at 88 euros. The consensus thus reflects some caution regarding the execution challenges in the group's pipeline.
